首页> JNCI cancer spectrum> Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

导出 LinkOut

翻译打印收藏纠错

第一作者： Andrea,Necchi

第一单位： Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.;Vita-Salute San Raffaele University, Milan, Italy.

作者： Andrea,Necchi ^[1] ; Rodryg,Ramlau ^[2] ; Alejandro,Falcón González ^[3] ; Arvind,Chaudhry ^[4] ; Tilman,Todenhöfer ^[5] ; Rana,Tahbaz ^[6] ; Elisa,Fontana ^[7] ; Patrizia,Giannatempo ^[8] ; Jean-Laurent,Deville ^[9] ; Damien,Pouessel ^[10] ; Shinkyo,Yoon ^[11] ; Thomas,Powles ^[12] ; Mathieu,Bernat ^[13] ; Manuel,Häckl ^[13] ; Michalina,Marszewska ^[13] ; Phil,McKernan ^[13] ; Mikael,Saulay ^[13] ; Federica,Scaleia ^[13] ; Marc,Engelhardt ^[13] ; Yohann,Loriot ^[14] ; Arlene,Siefker-Radtke ^[15] ; Maria,De Santis ^[16]

作者单位： Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.;Vita-Salute San Raffaele University, Milan, Italy. ^[1] Oncology Department, Poznań University of Medical Sciences, Poznań, Poland. ^[2] Department of Medical Oncology, Hospital Universitario Virgen Del Rocio, Sevilla, Spain. ^[3] Medical Oncology Associates, Summit Cancer Centers, Spokane, WA, USA. ^[4] Studienpraxis Urologie, Nürtingen, Germany. ^[5] Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany. ^[6] Sarah Cannon Research Institute, London, UK. ^[7] Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[8] Fédération de Cancérologie, CHU Timone, Marseille, France. ^[9] Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopôle), Toulouse, France. ^[10] Department of Oncology, Asan Medical Center, Seoul, Republic of Korea. ^[11] Barts Cancer Centre, Barts Health NHS Trust, London, UK. ^[12] Basilea Pharmaceutica International Ltd, Allschwil, Switzerland. ^[13] Medical Oncology Department, Institut Gustave Roussy, Villejuif, France. ^[14] The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[15] Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany.;Department of Urology, Medical University of Vienna, Vienna, Austria. ^[16]

医学主题词人类(Humans);男(雄)性(Male);女(雌)性(Female);老年人(Aged);中年人(Middle Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);受体, 成纤维细胞生长因子, 3型(Receptor, Fibroblast Growth Factor, Type 3);受体, 成纤维细胞生长因子, 1型(Receptor, Fibroblast Growth Factor, Type 1);老年人, 80以上(Aged, 80 and over);受体, 成纤维细胞生长因子, 2型(Receptor, Fibroblast Growth Factor, Type 2);膀胱肿瘤(Urinary Bladder Neoplasms);泌尿系肿瘤(Urologic Neoplasms);成年人(Adult);蛋白激酶抑制剂(Protein Kinase Inhibitors);癌, 移行细胞(Carcinoma, Transitional Cell)

DOI 10.1093/jncics/pkae030

PMID 38627238

发布时间 2024-05-30

基金项目

::Basilea Pharmaceutica:: ::Basilea Pharmaceutica::

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

JNCI cancer spectrum

2024年8卷3期

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

JNCI cancer spectrum

2024年8卷3期

检索历史清除

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

JNCI cancer spectrum

相似文献

同项目论文

JNCI cancer spectrum

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

JNCI cancer spectrum

相似文献

同项目论文

JNCI cancer spectrum

相关期刊

检索历史清除